OPTIMA

Optimal treatment for patients with solid tumours in Europe through artificial intelligence
OPTIMA logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 23
Grant agreement number
101034347

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
10 459 997
EFPIA in kind
10 579 800
Other
265 483
Total Cost
21 305 280

Summary

Advances in research mean that for many cancers, there are more treatment options than ever. Physicians face a growing number of diagnostic tests, treatments and guidelines, making it increasingly challenging to ensure each patient receives the right treatment.

The aim of OPTIMA is to harness the power of artificial intelligence to advance treatments and facilitate decision-making for physicians and patients with prostate, breast and lung cancer.

At the heart of OPTIMA will be Europe’s first interoperable, large scale oncology data and evidence generation platform with data from over 200 million people. The platform, which will be GDPR (General Data Protection Regulation) compliant, will host data sets, data analysis tools, federated learning tools, and artificial intelligence (AI) tools.

The project will use the platform to drive the generation of new knowledge by developing advanced analytics and AI models to identify, prioritise and fill the main knowledge gaps in prostate, breast and lung cancer, and propose improved clinical guideline recommendations. Finally, they will develop AI-based decision support tools that can help clinicians, together with their patients, make treatment decisions based on the leading clinical practice guidelines.

By designing the platform based on the needs of clinicians and patients, and by including the major guideline offices for prostate, breast and lung cancer, the project is well placed to have an impact care down the line.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Amgen, Brussels, Belgium
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Pfizer Limited, Sandwich, Kent , United Kingdom
Universities, research organisations, public bodies, non-profit groups
  • Association Eisbm, Vourles, France
  • Deutsche Krebsgesellschaft Ev, Berlin, Germany
  • Erasmus Universitair Medisch Centrum Rotterdam, Rotterdam, Netherlands
  • European Organisation For Research And Treatment Of Cancer Aisbl, Brussels, Belgium
  • European Respiratory Society, Lausanne, Switzerland
  • Fundacio Institut Universitari Pera La Recerca A L'Atencio Primaria De Salut Jordi Gol I Gurina, Barcelona, Spain
  • Helmholtz-Zentrum Dresden-Rossendorf Ev, Dresden, Germany
  • Institut De Cancerologie De L'Ouest, Angers, France
  • Ludwig-Maximilians-Universitaet Muenchen, Munich, Germany
  • Lunds Universitet, Lund, Sweden
  • Queen Mary University Of London, London, United Kingdom
  • Tartu Ulikool, Tartu, Estonia
  • The University Court Of The University Of Aberdeen, Aberdeen, United Kingdom
  • Universita Vita-Salute San Raffaele, Milano, Italy
  • Universitat Wien, Vienna, Austria
  • Universiteit Maastricht, Maastricht, Netherlands
  • University College London, London, United Kingdom
  • University of Oxford, Oxford, United Kingdom
  • Uppsala Universitet, Uppsala, Sweden
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arttic Innovation GMBH, Munchen, Germany
  • Gmv Soluciones Globales Internet Sau, Tres Cantos, Spain
  • Information Technology For Translational Medicine (Ittm) SA, Esch-sur-Alzette, Luxembourg
  • Istituto Europeo Di Oncologia SRL, Milan, Italy
  • Owkin France, Paris, France
  • Smart Reporting GMBH, München, Germany
  • Stichting European Urological Foundation, Arnhem, Netherlands
  • Ttopstart BV, Bilthoven, Netherlands
  • Ydeal.Net Software Lda, Santa Maria da Feira, Portugal
Patient organisations
  • European Cancer Patient Coalition, Brussels, Belgium
  • European Lung Foundation, Sheffield, United Kingdom
Third parties
  • European Lung Foundation Europe, Brussels, Belgium
Non EFPIA companies
  • Helios Klinikum Emil Von Behring GMBH, Berlin, Germany
Project coordinator
James N'Dow
Stichting European Urological Foundation